Published • loading... • Updated
CorFlow meets performance goals in MOCA II trial
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
CorFlow meets performance goals in MOCA II trial
CoFI CorFlow Therapeutics has announced milestones in advancing its clinical programme, reaching phase 1 of the MOCA II US Food and Drug Administration (FDA) pivotal trial. Safety and performance goals were met with ST-segment elevation myocardial infarction (STEMI) patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis b…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
